Key facts
- This page summarizes Jeffrey Busch's Form 4 filing for THERALINK TECHNOLOGIES, INC..
- 6 reported transactions and 6 derivative rows are listed below.
- Accepted by SEC: 02 Feb 2024, 20:10.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
Other
Award
Award
Other
Award
Award
Additional SEC filing notes
Footnote F1
Assumes a fixed conversion price of $0.003, but such conversion price is subject to adjustment as set forth in the debenture and warrant, respectively.
Footnote F2
The Reporting Person was issued a 10% Original Issue Discount ("O.I.D.") Senior Secured Convertible Debenture in the principal amount of $309,485 and 88,424,286 warrants in exchange for a demand promissory note in the principal amount of $250,000 previously issued to the Reporting Person.
Footnote F3
The debentures and warrants acquired by the Reporting Person are subject to mandatory conversion upon the occurrence of certain events, as outlined in the debentures and warrants. The original maturity date of the debentures was subsequently extended to February 29, 2024.
Footnote F4
Excludes shares issuable at the election of the Reporting Person upon conversion of accrued interest (both past and future) into shares of common stock.
Footnote F5
Expiration Date in the event a Qualified Offering is not consummated prior to the maturity date of the debentures the Warrants are issued in connection with.
Footnote F6
The Reporting Person purchased a 10% O.I.D. Senior Secured Convertible Debenture in the principal amount of $55,000 and 15,714,286 Warrants for an aggregate purchase price of $50,000 in a private placement offering that closed on November 29, 2022.
Footnote F7
The Reporting Person purchased a 10% O.I.D. Senior Secured Convertible Debenture in the principal amount of $155,100 and 44,314,286 Warrants for an aggregate purchase price of $141,000 in a private placement offering that closed on April 22, 2023.